Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
Subscribe To Our Newsletter & Stay Updated